Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation

Article Hematology

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

Akshay Sharma et al.

Summary: This study examined the characteristics and outcomes of HSCT recipients after developing COVID-19. It found that recipients of autologous and allogeneic HSCT who develop COVID-19 have poor overall survival rates. Factors such as age, sex, and time since transplantation were associated with higher risk of mortality in HSCT recipients.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Editorial Material Hematology

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT

Rabah Redjoul et al.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Peter Bergman et al.

Summary: This prospective clinical trial investigated the safety and efficacy of the BNT162b2 mRNA vaccine in immunocompromised patients and healthy controls. The vaccine was found to be safe in immunocompromised patients, but with a lower seroconversion rate compared to healthy controls. Additional vaccine doses may be needed to improve immunity in certain immunocompromised patient groups.

EBIOMEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

WHO International Standard for anti-SARS-CoV-2 immunoglobulin

Paul A. Kristiansen et al.

LANCET (2021)

添加到收藏夹

Article Immunology

Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay

Isabel Brand et al.

Summary: Adaptive immune responses to structural proteins of the SARS-CoV-2 virus play a crucial role in protection against COVID-19. This study found that convalescent COVID-19 patients still exhibit broad T cell reactivity to multiple SARS-CoV-2 structural proteins over 200 days after infection. The study also showed a loose but significant correlation between anti-Nucleocapsid antibody titer and the magnitude and breadth of the T cell response.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Hematology

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy

Binod Dhakal et al.

BLOOD (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients

Rabah Redjoul et al.

LANCET (2021)

添加到收藏夹

Article Oncology

COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey

Per Ljungman et al.

Summary: The study reveals that COVID-19 patients who have undergone allogeneic or autologous hematopoietic cell transplantation are at high risk of developing lower respiratory tract disease, requiring ICU admission, and have increased mortality rates.

LEUKEMIA (2021)

添加到收藏夹

Article Hematology

Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study

Ron Ram et al.

Summary: In this prospective evaluation, the BNT162b2 mRNA COVID-19 vaccine showed good tolerability and impressive immunogenicity in patients after allogeneic HCT or CART. While most adverse events were mild and transient, some significant hematologic events were observed, indicating the need for close monitoring of patients.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation

相关参考文献

导出引文

分享论文